$26.09
0.19% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Rigel Pharmaceuticals, Inc. Stock price

$26.09
+11.93 84.25% 1M
+17.02 187.49% 6M
+11.59 79.93% YTD
+16.24 164.82% 1Y
-3.11 10.65% 3Y
+2.79 11.97% 5Y
+5.89 29.16% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.05 0.19%
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Key metrics

Market capitalization $459.58m
Enterprise Value $458.70m
P/E (TTM) P/E ratio 120.45
EV/FCF (TTM) EV/FCF 42.79
EV/Sales (TTM) EV/Sales 2.91
P/S ratio (TTM) P/S ratio 2.92
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 18.97%
Revenue (TTM) Revenue $157.47m
EBIT (operating result TTM) EBIT $9.50m
Free Cash Flow (TTM) Free Cash Flow $10.72m
Cash position $61.11m
EPS (TTM) EPS $0.22
P/E forward 90.79
P/S forward 2.72
EV/Sales forward 2.71
Short interest 3.84%
Show more

Is Rigel Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Rigel Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

2x Buy
33%
4x Hold
67%

Analyst Opinions

6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Rigel Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
157 157
19% 19%
100%
- Direct Costs 17 17
355% 355%
11%
141 141
9% 9%
89%
- Selling and Administrative Expenses 108 108
1% 1%
69%
- Research and Development Expense 21 21
43% 43%
13%
11 11
164% 164%
7%
- Depreciation and Amortization 1.92 1.92
55% 55%
1%
EBIT (Operating Income) EBIT 9.50 9.50
150% 150%
6%
Net Profit 3.88 3.88
116% 116%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Rigel Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rigel Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
14 days ago
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, at 9:30 am GMT (4:30 am EST).
Neutral
Seeking Alpha
18 days ago
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2024 Earnings Call Transcript
Neutral
PRNewsWire
19 days ago
Third quarter total revenue of $55.3 million, which includes TAVALISSE® net product sales of $26.3 million, REZLIDHIA® net product sales of $5.5 million and GAVRETO® net product sales of $7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan, the Republic of Korea and Taiwan, recording an upfront cash payment of $10.0 mill...
More Rigel Pharmaceuticals, Inc. News

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Head office United States
CEO Raul Rodriguez
Employees 147
Founded 1996
Website www.rigel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today